HIV

News

Switch study says patients prefer ViiV’s injectable HIV drug

When ViiV Healthcare and Johnson & Johnson launched their once-monthly injectable HIV treatment Cabenuva in 2021, they predicted that patients would prefer that option

News

Gilead, Teva cleared in $3.6bn ‘pay-for-delay’ trial

The jury in a California court has sided with Gilead Sciences and Teva in a lawsuit that accused the drugmakers of conspiring to delay the launch of generic versions of th

News

Gilead emerges victorious from HIV PrEP patent trial

A US court has sided with Gilead Sciences in a dispute with the US government centred on the use of HIV medicines for pre-exposure prophylaxis.

News

Gilead and US Government square up in court over PrEP

Gilead Sciences will go to court this week to argue that it does not need to pay the US Government a share of the profits it has made on the use of its HIV drugs for pre-e

News

GSK licenses out new HIV PrEP drug in poorer nations

GSK’s majority-owned HIV unit ViiV has agreed licensing deals with a trio of generic manufacturers to make its recently-approved long-acting drug for pre-exposure prophyla

News